

Controlled substance	Drug code	Schedule
Lisdexamfetamine	1205	II
Methylphenidate	1724	II
Pentobarbital	2270	II
Nabilone	7379	II
4-Anilino-N-phenethyl-4-piperidine (ANPP)	8333	II
Cocaine	9041	II
Codeine	9050	II
Dihydrocodeine	9120	II
Oxycodone	9143	II
Hydromorphone	9150	II
Ecgonine	9180	II
Hydrocodone	9193	II
Levorphanol	9220	II
Meperidine	9230	II
Meperidine intermediate-A	9232	II
Meperidine intermediate-B	9233	II
Meperidine intermediate-C	9234	II
Methadone	9250	II
Methadone intermediate (4-cyano-2-dimethylamino-4,4-diphenylbutane)	9254	II
Morphine	9300	II
Oripavine	9330	II
Thebaine	9333	II
Opium tincture	9630	II
Opium, powdered	9639	II
Opium, granulated	9640	II
Oxymorphone	9652	II
Noroxymorphone	9668	II
Alfentanil	9737	II
Remifentanil	9739	II
Sufentanil	9740	II
Carfentanil	9743	II
Tapentadol	9780	II
Fentanyl	9801	II

The company plans to bulk manufacture the listed controlled substances for the production of active pharmaceutical ingredients and analytical reference standards for sale to its customers. The company plans to manufacture the above listed controlled substances as clinical trial and starting materials to make compounds for distribution to its customers. No other activities for these drug codes are authorized for this registration.

**Thomas Prevoznik,**  
*Deputy Assistant Administrator.*  
 [FR Doc. 2026-06524 Filed 4-2-26; 8:45 am]  
**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**  
 [Docket No. DEA-1698]

**Bulk Manufacturer of Controlled Substances Application: Research Triangle Institute**

**AGENCY:** Drug Enforcement Administration, Justice.  
**ACTION:** Notice of application.

**SUMMARY:** Research Triangle Institute has applied to be registered as a bulk manufacturer of basic class(es) of

controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.  
**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before June 2, 2026. Such persons may also file a written request for a hearing on the application on or before June 2, 2026.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this

is notice that on March 3, 2026, Research Triangle Institute, 3040 East Cornwallis Road, Hermann Building, Room 106, Durham, North Carolina 27713, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols	7370	I

The company plans to bulk manufacture the listed controlled substance synthetically for distribution to its customers for research and as analytical reference standards. No other activity for this drug code is authorized for this registration.

**Thomas Prevoznik,**  
*Deputy Assistant Administrator.*  
 [FR Doc. 2026-06522 Filed 4-2-26; 8:45 am]  
**BILLING CODE 4410-09-P**